Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Heatwave
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns
India

COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns

COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns
Written by Siddhant Pandey
Jan 04, 2021, 10:54 pm 3 min read
COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns

Bharat Biotech MS Krishna Ella on Monday said the company has "tremendous experience" in developing vaccines and their vaccine, COVAXIN, is "200% safe." The statement comes amid backlash over emergency approval for the restricted use of the vaccine, which was granted on Sunday. Some experts and the Opposition have questioned the regulatory approval in the absence of efficacy data from Phase III trials.

Vaccine
COVAXIN Phase III trials still underway

COVAXIN is an inactivated vaccine, i.e., it uses an inactivated or killed pathogen (SARS-CoV-2) to trigger an immune response. It has been developed jointly by Bharat Biotech and the Indian Council of Medical Research's National Institute of Virology (ICMR-NIV). Phase III trials of the vaccine are yet to be completed, however, at least 22,500 out of 25,800 intended subjects have been vaccinated.

Quote
'Merck's Ebola vaccine received emergency approval without trial'

Addressing a presser, Ella said, "Merck's Ebola vaccine never completed a human clinical trial at all but WHO gave emergency authorization for Liberia and Guinea." He said, "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party. Many people are just gossiping. It's just a backlash against Indian companies."

Experience
'Not a company without experience; we don't deserve this'

Ella said the company does not deserve the backlash as they have submitted sufficient data that is available on the internet. "We are not a company without experience in vaccines," he said, "We are touching 123 countries. We are the only company that has got such extensive experience and extensive publication in review journals." COVAXIN trials were conducted in over 12 countries, he added.

Quote
'People should have patience to read our articles'

Ella further said, "Many people say that I am not transparent in my data. I think people should have the patience to read on the internet and how many articles we have published. More than 70 articles have been published in various international journals."

Safety
COVAXIN showed less than 10% adverse reactions, says Ella

Ella said, "COVAXIN has shown less than 10% adverse reactions, while others have 60-70% adverse reactions. AstraZeneca was giving 4g paracetamol to volunteers to suppress such reactions. We haven't given paracetamol to any volunteer." "I can assure you our vaccine is 200% safe," he said. Ella also requested a week's time for confirmed data on the vaccine's efficacy against the new strain of coronavirus.

New strain
COVAXIN will work better against new strain, says government

A new strain of SARS-CoV-2 has caused a stir as authorities say it can be as much as "70% more infectious." India has reported at least 52 such cases so far. Health Minister Dr. Harsh Vardhan and ICMR Director-General Dr. Balram Bhargava have said that COVAXIN has a better chance against the new strain as it uses a killed version of the whole virus.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
Harsh Vardhan
Ministry of Health and Family Welfare
Coronavirus
Balram Bhargava
Bharat Biotech
Related
Latest
Maserati Cielo convertible to break cover on May 25
Maserati Cielo convertible to break cover on May 25 Auto
5 films that deal with postpartum depression
5 films that deal with postpartum depression Entertainment
French Open, Rafael Nadal vs Novak Djokovic: Rivalry in numbers
French Open, Rafael Nadal vs Novak Djokovic: Rivalry in numbers Sports
Statistical comparison of 'Big Titles' between Djokovic, Federer, and Nadal
Statistical comparison of 'Big Titles' between Djokovic, Federer, and Nadal Sports
Vivo S15 Pro announced with MediaTek Dimensity 8100 SoC
Vivo S15 Pro announced with MediaTek Dimensity 8100 SoC Technology
Harsh Vardhan
Meet Mansukh Mandaviya, who replaced Harsh Vardhan as Health Minister
Meet Mansukh Mandaviya, who replaced Harsh Vardhan as Health Minister Politics
Harsh Vardhan, Ravi Shankar, Prakash Javadekar quit before Cabinet reshuffle
Harsh Vardhan, Ravi Shankar, Prakash Javadekar quit before Cabinet reshuffle Politics
July has come, vaccines haven't, says Rahul; BJP hits back
July has come, vaccines haven't, says Rahul; BJP hits back Politics
India strongly opposes 'COVID-19 vaccine passport' idea at G7 meet
India strongly opposes 'COVID-19 vaccine passport' idea at G7 meet India
Gehlot slams Dr. Vardhan on issue of availability of vaccines
Gehlot slams Dr. Vardhan on issue of availability of vaccines Politics
More News
Ministry of Health and Family Welfare
NEET-PG 2022 exam not postponed, fake notice being circulated: NBE
NEET-PG 2022 exam not postponed, fake notice being circulated: NBE India
All existing COVID-19 restrictions to be lifted from March 31
All existing COVID-19 restrictions to be lifted from March 31 India
India reports 1,761 more COVID-19 cases, 127 deaths
India reports 1,761 more COVID-19 cases, 127 deaths India
India's fertility rate drops to 2. What does it mean?
India's fertility rate drops to 2. What does it mean? India
COVID-19 vaccine Corbevax's samples cleared by India's apex testing laboratory
COVID-19 vaccine Corbevax's samples cleared by India's apex testing laboratory India
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
Balram Bhargava
ICMR chief explains why COVID-19 second wave is affecting youngsters
ICMR chief explains why COVID-19 second wave is affecting youngsters India
SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally India
Bharat Biotech allowed COVAXIN trials on children aged 12+
Bharat Biotech allowed COVAXIN trials on children aged 12+ India
Government assures vaccine will work against new COVID-19 strain
Government assures vaccine will work against new COVID-19 strain India
COVID-19 task force details plan to detect new coronavirus strain
COVID-19 task force details plan to detect new coronavirus strain India
More News
Bharat Biotech
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
COVAXIN supply to be increased as teens get COVID-19 vaccines
COVAXIN supply to be increased as teens get COVID-19 vaccines India
Are Indian vaccines effective against Omicron? Here's what manufacturers say
Are Indian vaccines effective against Omicron? Here's what manufacturers say India
COVAXIN gets WHO approval for emergency use listing
COVAXIN gets WHO approval for emergency use listing India
More News
Related
COVAXIN trial data for children aged 2-18 submitted to DCGI
COVAXIN trial data for children aged 2-18 submitted to DCGI India
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN India
COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech
COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech India
Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil
Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil Business
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022